The treatment was developed by Urotronic, a medical technology company that specializes in treating urological conditions, and uses a drug-coated balloon to treat benign prostatic hyperplasia by dilating the urethra and allowing improved urine flow, Urotronic said in a July 11 news release.
The system results in substantial, immediate improvements in BPH patient symptoms and functions that was maintained throughout the four-year follow-up period, according to findings from clinical trials.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
